The Dermavant Sciences logo.
We Are Dermavant

BRINGING CLEAR SOLUTIONS TO CHRONIC SKIN CONDITIONS

Explore VTAMA® (tapinarof) cream, 1%

Skin Deserves More

Where skin meets science

Dermavant is changing the approach of how healthcare providers treat chronic skin conditions. By combining the power of science with breakthrough innovations and challenging the standard of care in immuno-dermatology, we’re working to bring clear solutions to patients who need them most.

Because skin health is more than just skin deep

Having vibrant skin is about more than looking good – it’s about feeling good. When chronic skin conditions begin to clear, patients’ self-confidence can start to shine.

Leading the way for change

We’re working to extend a pipeline that targets the unmet needs of people living with chronic skin conditions.

See how we’re innovating for patients

Explore Our Pipeline

VTAMA (tapinarof) cream, 1%

Explore Our Topical Therapy

Dermavant is now part of Organon

Dermavant Logo    Organon Logo
Dermavant Logo    Organon Logo

Together, we aim to deliver science that takes us closer to meaningful change for people with chronic skin conditions.

You are now leaving Dermavant.com

You are now leaving www.dermavant.com. Links to sites outside of Dermavant are provided as a resource to the viewer. Dermavant accepts no responsibility for the content of linked sites.

You are now leaving Dermavant.com

You are now leaving www.dermavant.com. Links to sites outside of Dermavant are provided as a resource to the viewer. Dermavant accepts no responsibility for the content of linked sites.

You are now leaving Dermavant.com

You are now leaving www.dermavant.com. Links to sites outside of Dermavant are provided as a resource to the viewer. Dermavant accepts no responsibility for the content of linked sites.

You are now leaving Dermavant.com

You are now leaving www.dermavant.com. Links to sites outside of Dermavant are provided as a resource to the viewer. Dermavant accepts no responsibility for the content of linked sites.

You are now leaving Dermavant.com

You are now leaving www.dermavant.com. Links to sites outside of Dermavant are provided as a resource to the viewer. Dermavant accepts no responsibility for the content of linked sites.

Important Safety Information

Indications: VTAMA® (tapinarof) cream, 1% is an aryl hydrocarbon receptor agonist indicated for:

  • the topical treatment of plaque psoriasis in adults.
  • the topical treatment of atopic dermatitis in adults and pediatric patients 2 years of age and older.

Adverse Events: In plaque psoriasis, the most common adverse reactions (incidence ≥1%) were: red raised bumps around the hair pores (folliculitis); pain or swelling in the nose and throat (nasopharyngitis); skin rash or irritation, including itching and redness, peeling, burning, or stinging (contact dermatitis); headache; itching (pruritus); and flu (influenza).

Adverse Events: In atopic dermatitis, the most common adverse reactions (incidence ≥1%) were: upper respiratory tract infection; red raised bumps around the hair pores (folliculitis); lower respiratory tract infection; headache; asthma; vomiting; ear infection; pain in extremity; and stomach-area (abdominal) pain.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

See full Prescribing Information and Patient Information.